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INTRODUCTION
Topoisomerase II enzymes, 1 break double strands of DNA and induce topological changes in DNA. 2 Etoposide, a topoisomerase II poison, stabilizes the cleavable complex formation converting topoisomerase into physiological toxins that introduce high levels of transient protein associated breaks in the genome of treated cells. 3 Levels of topoisomerase II are generally elevated in cells that are undergoing rapid proliferation and due to the mechanism of drug action, the higher the physiological concentration of topoisomerase II, the more lethal the poison becomes.
Human telomeres are specialized DNA-protein structures localized at the ends of chromosomes. They are composed of tandemly repeated hexanucleotides TTAGGG, bound to specific proteins. Their shortening with each round of DNA replication is caused by different mechanisms, one of these being their sensitivity to DNA damage. Thus, telomere shortening can greatly be accelerated or decelerated by controlling oxidative stress within the cells. 4 Telomeres end in single stranded overhangs of the G-rich strand, which appear to be essential for telomeric higher order structure, 5 and possibly for the generation of DNA damage signals from telomeres. [6] [7] [8] In the vast majority of cancer cells, telomere shortening is counteracted by telomerase, a reverse transcriptase that uses an RNA template to add telomeric repeats onto the ends of chromosomes. 9, 10 Inhibition of telomerase by different methods has been shown to lead not only to progressive telomere shortening and ensuing cell death, 11 but also to telomere length-independent apoptosis induction. 12 Etoposide has been shown to generate topoisomerase DNA cleavable sites in telomeres in vitro and in vivo. 13 Contradictory data exists on the interaction between etoposide and telomerase. Upregulation of telomerase activity was observed in the human leukemic cell line HL60, 14, 15 and a number of pancreatic tumor cell lines after etoposide treatment. 16 However a decrease in telomerase activity was observed in hepatocarcinomas and other leukemic cell lines, 17 and no change in levels of telomerase in haematopoietic, 18 and nasopharyngeal carcinoma cells. 19 There is evidence that inhibition of telomerase sensitizes cells to topoisomerase II poisons including etoposide, 20, 21 and that overexpression of the catalytic subunit of telomerase (hTERT) in normal cells led to an increased resistance against etoposide. 20, 22 However, others could not confirm a telomerase dependency of the sensitivity of various tumor cells to etoposide. 23, 24 Given these inconsistent results, we decided to examine whether there is a role for the telomere/telomerase complex in etoposide induced cell death. Neither telomere length, telomere strand break frequency, or length of G-rich telomeric single-stranded overhangs changed in etoposide-treated cells before onset of apoptosis. We conclude that telomeres are not directly involved in the signalling pathway to etoposide-induced tumor cell growth arrest or apoptosis. However, telomerase was transiently upregulated in response to etoposide treatment in SHSY5Y cells and overexpression of telomerase protected human cells against etoposide-induced apoptosis, probably by an indirect mechanism.
MATERIALS AND METHODS
Cell Culture and Drug Solutions. The neuroblastoma cell line SHSY5Y, 25 was obtained from ATCC, USA and acute lymphoblastic T cells 1301 were from Dako, Denmark. Cells were grown in RPMI medium plus 10% foetal calf serum at 37˚C under air plus 5% CO 2 . MRC5 human fibroblasts were obtained from the ECACC and grown in DMEM. MRC-5 fibroblasts at PD 33 were telomerized using retroviral supernatant from ΦNX cells transfected with the retroviral vector pLCP-hTERT (Clontech) containing the gene for the human reverse transcriptase (hTERT) under control of the CMV promoter and selected with 0.75 µg/ml puromycin. Lifespan of MRC-hTERT was greatly extended for at least 120 PD. Telomerase activity (analysed in a TRAP assay) was comparably high to tumor cells, telomeres (measured in southern blot) were stably maintained at around 9 kb. Etoposide was dissolved in methanol prior to each experiment and diluted into medium. All reagents were acquired from Sigma-Aldrich (Poole, UK).
Sulphorhodamine B (SRB) Assay. Cells were seeded into multiple 96 well plates and incubated for 24 hours before treatment with varying concentrations of etoposide for four hours. Daily a plate would be fixed with 50% trichloroacetic acid up to 6 days after treatment. All plates were then stained with 0.4% SRB in 1% acetic acid for 30 mins, washed with 10 mM Tris pH 10.5 for 10 mins and read on a spectrophometric plate reader at 570 nm.
Cell Counting and Apoptosis. After appropriate etoposide treatment, non adherent and adherent cells were collected in RPMI plus 10% FCS, counted using a haemocytometer (VWR International, Leicester, UK) and stained with 10 µg/ml propidium iodide for 15 mins at 4˚C to determine the number of cells with intact plasma membrane. The cells were immediately used for apoptosis analysis in a PAS-PPCS flow cytometer (Partec GmbH, Munster, Germany). Apoptosis was assessed as the fraction of small, granular apoptotic cells that are distinguishable from viable cells by their lower forward and higher sideward light scatter. 26 Immunofluoresence. Cells were grown onto coverslips, treated with etoposide, fixed with 2% paraformaldehyde in PBS for 10 mins and permeabilized in PBG (0.2% cold water fish skin gelatine, 0.5 % BSA in PBS) with 0.5 % Triton X-100 for 45 mins at room temperature. Cells were incubated with anti phosphor histone H2A.X (Upstate, Cat#05-636) in PBG with 0.5% Triton X-100 and washed. Alexa fluor 594 goat anti mouse IgG (Molecular probes Cat# A11005) was used as a secondary antibody. Cells were stained with DAPI and imaged in a Zeiss epifluorescence microscope.
Fluorescence Detected Alkaline DNA Unwinding Assay (FADU). Single and double strand breaks were measured using the semi automated FADU assay. 27 Briefly cells were treated with etoposide for four hours, washed in PBS and lysed in 0.25 M meso-inositol, 1M MgCl 2 , 10 mM Na 2 P0 4 /NaH 2 PO 4 , pH 7.2. The lysed cells were transferred onto a 96-well plate (replicates of [8] [9] [10] , kept at 4˚C, and denaturation buffer (9 M urea, 10 mM NaOH, 25 mM CDTA (trans-1,2-diaminocyclohexane-N,N,N'N'-tetraacetic acid), 0.1% SDS) was added, followed by an alkali solution (200 mM NaOH, 40% denaturation buffer) at 37˚C for 90 mins. DNA was stained with the intercalating dye SYBR Green (diluted 1:25,000 in 13 mM NaOH) and fluorescence was measured in a fluorescence reader Spectrafluor Plus (Tecan, Crailsheim, Germany) at λex 492 nm and λem 520 nm. The fluorescence intensity is inversely correlated to the number of DNA strand breaks present at the time of lysis. DNA damage percentage was calculated as 100x (P 0 -P x ) / P 0 , with P 0 : fluorescence intensity of an untreated control sample and P x : fluorescence intensity of the treated cell sample.
Cell Cycle. Non adherent and adherent treated cells were collected, washed in PBS and fixed in 70% ice cold ethanol for 1 hour. Cells were washed in PBS, resuspended in DAPI stain/PBS and analysed in a PAS-PPCS flow cytometer using UV excitation (Partec GmbH, Munster, Germany).
BrdU Incorporation. Cells were treated with etoposide for 48 hours and incubated with 20 µM 2-bromo-5-deoxuridine (BrdU) for 1 hour. Cells were then fixed in 70% ice cold ethanol, washed in PBS plus 0.5% bovine serum albumin (BSA) and denatured in 2M HCl in PBS plus 0.5% BSA at room temperature for 20 mins. After neutralization for 2 mins in 0.1 M sodium borate pH 8.5 cells were stained with FITC-AntiBrdU (Pharmingen Cat#33284X, 20 µl of antibody in 30 µl of dilution buffer) or FITC-IgG control (Pharmingen Cat# 35404X) for 30 mins. Cellular DNA was stained with 10 µg/ml propidium iodide for 30 mins and samples were analysed in PAS-PPCS flow cytometer (Partec GmbH, Munster, Germany) with FL1 in log4 scale and FL3 in linear scale.
Telomere and Overhang Lengths. Cells were embedded in 0.65% low melting agarose plugs at a density of 10 7 cells/ml before treatment with proteinase K. 28 DNA was completely digested by Hinf1 (60 U per plug; Roche) at 37˚C. Plugs were analysed in a 1% agarose gel by pulsed field gel electrophoresis (Biorad) at 3 V/cm for SHSY5Y cells and 5.5 V/cm for 1301 cells for 17 hours with a switching time of 2 to 10 in 0.5 x TBE. To measure telomere restriction fragment lengths in SHSY5Y cells, the gel was dried at room temperature, denatured (1.5 M NaCl, 0.5 M NaOH) for 30 mins, neutralized (1.5 M Nacl, 0.5 M Tris-HCl, pH 7.4) for 30 mins and in-gel hybridized with 32P-γ-ATP (TTAGGG) 4 at 43˚C for 16 hours. For the 1301 cells, gels were southern blotted to Hybond-N+ membranes and hybridized with 32P-γ-ATP (TTAGGG) 4 at 43˚C for 16 hours. All gels/ blots were washed 4 times in 0.2 x SSC/0.2 x SSC & 0.1% SDS at 43˚C for 30 mins each and then exposed to a phosphoimager screen overnight. Signals were visualized using a phosphoimager (Storm 820, Molecular Dynamics, Amersham). Average fragment length per lane was calculated as weighted mean of the optical density using the AIDA densitometry software (Raytek, Sheffield, UK).
The length of single-stranded terminal overhangs in telomeres was measured by in-gel hybridization of telomeric probes onto nondenatured DNA as described, 28, 29 with the following modifications: In-gel hybridization with 32P-γ-ATP (CCCTAA) 4 was performed on non denatured gels at 37°C for 16 hours. Gels were then washed as for telomeres though at 37˚C and visualized. Under these conditions, only single-stranded G-rich DNA is available as target for hybridization. Afterwards, DNA was denatured and gels were hybridized as above to obtain the total telomeric signal. To test for unspecific degradation of DNA, gels were rehybridized with the minisatellite probe (CAC) 8 .
Single Strand Breaks in the G Rich Strand of Telomeres. DNA was digested overnight at 37˚C with Hinf1. Digested DNA was preincubated for 2 hours in 1x alkaline buffer (50 mM NaOH, 1 mM EDTA) and then electrophoresed at 26 V for 20 hours for SHSY5Y cells and 40 V for 24 hours for 1301 cells in 0.7% agarose in alkaline buffer. Gels were then neutralized (1.5 M Nacl, 0.5 M Tris-HCl, pH 7.4) for 1 hour and dried at room temperature. Gels were hybridized with 32P-γ-ATP (AATCCC) 4 at 43˚C for 16 hours and washed 4 times in 0.2 x SSC at 43˚C for 30 mins each. They were then exposed to a phosphoimager screen overnight. Signals were visualized using a phosphoimager (Storm 820, Molecular Dynamics, Amersham).
TRAP Assay. Telomerase PCR ELISA (Roche) was used for analysis of telomerase activity in SHSY5Y cells using 2 µg of protein according to the manufacturer's recommendations.
RESULTS
Etoposide Induces S Phase Arrest and Apoptosis. Treatment of both cell lines with etoposide induced arrest of net growth and cell loss in a concentration-dependent manner. IC 50 values were measured by the sulphorhodamine B (SRB) assay and/or cell counting for a bolus treatment which lasted for 4 h ('short treatment') and a continuous treatment for at least 48 h (Table 1) . These two regimens, spanning concentration ranges from 0-350 µM for the short treatment and 0-5 µM for the continuous treatment, were used in all subsequent experiments.
Short treatments with etoposide in concentrations of 100 µM and above induced significant apoptosis in both SHSY5Y (Fig. 1A) and 1301 cells (Fig. 1B) .
Continuous treatment with concentrations above 1 µM also induced significant apoptosis in SHSY5Y (Fig. 1C) and less so in 1301 cells (Fig. 1D) , despite a significant inhibition of net growth (Table 1 ). In fact, the majority of non-apoptotic cells were growth-arrested at 2 days after the onset of treatments. Measurement of the cellular DNA content in SHSY5Y cells revealed significant increases of the fraction of cells in S phase at 48 h after a short etoposide treatment ( Fig. 2A) and after continuous treatment (data not shown). Neither of these cells incorporated BrdU (Fig. 2B) . We conclude that etoposide treatment induces S phase arrest and apoptosis with the relative frequencies of these responses being dependent on both treatment regime and cell type.
Etoposide Triggers a DNA Damage Response. FADU measurements confirmed the expected concentration-dependent rise of DNA strand breaks immediately after a 4 h treatment in both SHSY5Y cells (Fig. 3A) and 1301 cells (Fig. 3B) , which correlates well with the observed frequencies of apoptotic cells after short term treatment (Fig. 1A and B) . We observed a better strand break repair capacity of 1301 cells, resulting in significantly less damage remaining after a further 4 h incubation (compare Fig. 3A and B) , which might be related to the ability of 1301 cells to redirect their response to low etoposide concentrations from apoptosis towards growth arrest. The DNA damage response was examined by staining with an antibody recognizing the phosphorylated form of histone H2A.X (γ-H2A.X). γ-H2A.X is a major component of DNA damage induced foci of proteins, which function as a signal transducer between DNA strand breaks and the cellular 30 DNA damage foci were clearly evident in the majority of the cells even at 24 h after a short treatment with as low as 15 µM etoposide (Fig. 3C) . Etoposide Treatment Does Not Influence Telomere Length. Telomere shortening is a major mechanism to induce telomere uncapping and thus to signal growth arrest and/or apoptosis. [30] [31] [32] To find out whether etoposide-induced growth arrest and apoptosis was preceded or accompanied by telomere shortening, telomere restriction fragment lengths were examined by an in gel hybridization technique using all treatment regimes on both cell lines. Average fragment lengths were calculated for each lane as weighted mean of the optical density and are shown as white bars. Neither short exposure (Fig. 4A) nor continuous treatment (Fig. 4B ) of SHSY5Y cells had any effect on telomere length. This was confirmed by quantitative evaluation (Fig. 4C and data not shown) . The same holds for the much longer telomeres in 1301 cells (Fig. 4D and data not shown) .
Yoon et al. 13 showed that the topoisomerase II cleavage site is 5' TTAGG*G 3' when etoposide was present. It was also suggested that not only telomere shortening, but also an abundance of DNA single-strand breaks in telomeres could lead to opening of the t-loop and uncapping of telomeres. 33 Thus, we next examined the G-rich telomeric strand separately using denaturing gel electrophoresis. There was no evidence of single stranded DNA breaks on the telomeric G-rich strand after either continuous treatment of SHSY5Y (Fig. 4E) or short exposure treatment of 1301 cells (Fig. 4F) .
Etoposide Does Not Influence the Length of Telomeric Single Stranded G-Rich Overhangs. Telomeric single stranded overhangs have been implicated in telomere structural maintenance, 5 and generation of a DNA damage/growth arrest response. 6, 7, 34 In order to test whether etoposide treatment might interfere with the integrity of the overhangs, we assessed overhang length by measuring the relative hybridization signal intensity of overhangs alone and whole telomeres. 29 Neither in continuously exposed SHSY5Y cells (Fig. 5A ) nor in 1301 cells after short treatment (Fig. 5B) could any significant change of the relative overhang length be observed. We conclude that etoposide treatment even at high concentrations does not induce degradation of the G-rich telomeric overhang.
Telomerase Activity Decreases Only after Onset of Apoptosis. Telomerase activity was measured by the semiquantitative TRAP ELISA in SHSY5Y cells under a continuous etoposide treatment at various time points and concentrations (Fig. 6 ). Increased telomerase activity was found in cells treated for 48 h with low concentrations of etoposide, which was significant for the treatment with 0.25 µM. At the same time, a significant decrease in telomerase activity became apparent after treatment with 5 µM etoposide, the highest concentration tested. 72 h of treatment with etoposide in con- (Fig. 6 ). At these time points and concentrations more than 50% of the cells are in apoptosis (Fig. 1C) . This suggests that telomerase is first activated in response to the cytotoxic treatment, and that the later decrease in telomerase activity is a consequence of etoposide-induced apoptosis rather than a possible cause.
Telomerase Protects Human Fibroblasts from Apoptosis after Continuous Etoposide Treatment. To examine whether telomerase expression could modify cellular responses to etoposide treatment, we stably transfected normal diploid human fibroblasts (MRC5) with hTERT. These cells display high telomerase activity and show greatly increased lifespan, 30 but the expression of hTERT elongates telomeres only slightly and does not change basal rates of apoptosis or growth arrest. We compared responses to etoposide treatment between parental MRC5 and MRC5-hTERT cells. Both strains are significantly less sensitive to etoposide than either SHSY5Y or 1301 cells. Treatment with 250 µM etoposide produced a strong DNA damage response in all cells, whether they were telomerase-negative or positive. Levels of γ-H2A.X staining are at saturation in essentially all cells following short exposure to etoposide (Fig. 7A ). Etoposide treatment with concentrations between 50 and 250 µM for 48 h induced significant apoptosis in parental MRC5 fibroblasts. However, hTERT-expressing fibroblasts were efficiently protected from apoptosis ( Fig. 7B ) and significantly increased apoptosis levels were only found after treatments with doses higher than 250 µM (data not shown). A similar protective effect of hTERT overexpression against the cytotoxicity of etoposide and other topoisomerase II poisons had been shown before in other human cell strains. 20, 22 
DISCUSSION
There are several lines of evidence to suggest that telomere/telomerase complexes could be important signal transduction intermediates in drug-induced cell growth arrest and apoptosis. First, telomeres are specifically sensitive to DNA damage induced by UV, 35 oxidative stress, 4, 36 and possibly, chemotherapeutic drugs including etoposide. 13 Second, dysfunctional telomeres trigger growth arrest and/or apoptosis via telomerespecific induction of DNA damage foci, also termed senescence-associated DNA damage foci. 30 Third, inhibition of telomerase sensitizes mice cells, 37 and human cells, 20, 21 towards cytotoxic drugs including etoposide. Accordingly, overexpression of the catalytic subunit of telomerase increased the resistance of cells against etoposide. 20, 22 Fourth, etoposide treatment of tumor cells has been claimed to shorten telomeres, 13 or to modify telomerase expression and/or activity. 38 However, a number of published results are contradictory. Some data, both in mice, 37 and in human cells, 23 suggest that it is telomere length rather than telomerase activity that modifies the sensitivity of cells to anticancer drugs. In contrast to that, arguments for a telomere length-independent protective action of telomerase per se were found in a number of different systems. 12, 20, 39 Other authors, however, did not detect any effect of telomerase inhibition on the sensitivity of tumor cells to etoposide. 23, 24 The present study shows that etoposide induced widespread DNA strand breaks and a classical DNA damage response as indicated by DNA damage foci formation. This was followed by a combination of growth arrest and apoptosis in a concentration-and cell strain-dependent manner.
To establish the role of telomeres in this process, we measured not only telomere length, but also length of single stranded telomeric Grich overhangs and the frequency of single-strand breaks in the G-rich strand of telomeres. Since the importance of a telomere-dependent signal transduction pathway, if it existed at all, might be different in cells with long and short telomeres, we examined one cell line with very short (SHSY5Y, average telomere length about 3.2 kbp) and one with extremely long (1301, average telomere length about 80 kbp) telomeres. None of the parameters mentioned above changed significantly in either cell line under the treatments despite induction of growth arrest and/or apoptosis. This is not in accordance with Yoon et al. 13 who show a slight shortening of telomere lengths in HeLa cells after treatment with etoposide. Whether this discrepancy to our results might be cell line-specific, is not clear. However, our data clearly establish that measurable telomeric damage, might it be shortening, accumulation of single strand breaks or deterioration of the G-rich overhang, is not necessary as a signal transduction intermediate in etoposide-induced tumor cell growth arrest and apoptosis.
We next examined telomerase activity levels in SHSY5Y cells after continuous exposure to etoposide. It had been shown that treatment with etoposide can transiently upregulate telomerase activity in some tumor cells. [14] [15] [16] Under our conditions of continuous treatment, we found a transient increase of telomerase activity after 48 h, which was significant under the lowest etoposide concentration. High concentrations of etoposide did not induce any immediate change in telomerase activity. However, they resulted in a decrease of telomerase activity with increasing concentration and time of treatment, which occurred after the massive onset of apoptosis. These results are in accordance with others. 18 Thus, downregulation of telomerase is a consequence, not a possible cause of etoposide-induced apoptosis or growth arrest. However, the possibility remains that telomerase is upregulated also in response to higher etoposide concentrations, but that this is masked by a parallel induction of apoptosis. Thus, upregulation of telomerase might be part of a compensatory response of tumor cells to cytotoxic treatments. In fact, upregulation of telomerase has been demonstrated in response to etoposide, [14] [15] [16] and to a wide variety of other cytotoxic agents including oxidative stress. 7 This is consistent with the idea of telomerase acting as a "survival factor". 12, 22, 39 Telomerase could promote survival either by compensating for telomeric damage or by some telomere-independent mechanism. Our present data cannot discriminate between these two possibilities: The constancy of telomere length under etoposide might be either due to negligible damage in this specific structure, or due to damage compensation by the action of telomerase. There are arguments in favor of a telomere-independent mechanism, however. Firstly, an overexpression of telomerase has been shown to induce the expression of a number of DNA damage response and repair genes, 39 which are known to act in a telomere-independent fashion. Second, if maintenance of telomere length and/or structure by telomerase were important for the resistance of tumor cells to cytotoxins, one should expect that telomerase knock-down would result in compromised telomeres, followed by early induction of apoptosis or growth arrest. In fact, telomerase knock-down induces apoptosis in a variety of tumor cells even under mild stress conditions. However, this occurs without any change in telomere length. 12, 20 In conclusion, our data show that SHSY5Y and 1301 cells respond to etoposide treatment by a combination of S phase arrest and apoptosis. While a transient activation of telomerase is evident under some conditions, which might be part of an attempted survival response, we find no indication that telomeres and/or telomeric damage play any preferential role as a signal transducer towards apoptosis and/or growth arrest in etoposide-treated tumor cells.
